PharmaShots | Incisive News in 3 Shots

Subscribe Now

Japanese Marketing Approval

Amgen and Astellas' Blincyto (blinatumomab- BiTE) Receives Japanese Marketing Approval for Treatment of R/R B-cell Acute Lymphoblastic Leukemia(ALL)

Amgen and Astellas' Blincyto (blinatumomab- BiTE) Receives Japanese Marketing Approval for Treatment of R/R B-cell Acute Lymphobla...

September 25, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us